ANALGESIC COMPOSITION OF TOPICALLY APPLIED NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND OPIOIDS

• US 20100143449A1
• Filed: 02/29/2008
• Published: 06/10/2010
• Est. Priority Date: 03/02/2007
• Status: Abandoned Application

• Current Assignee: Flamek Corp.
• Original Assignee: Flamek Corp.
• Inventors: Kolesnikov, Yuri
• Application Number:
  US12/449,912
• Publication Number:
  US 20100143449A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to pharmaceutical formulations comprising at least two compounds, one effecting opioid analgesia and one effecting cyclooxygenase 1 and 2 activity, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient. The pharmaceutical formulations of the present invention are used to prevent or relieve acute pain and chronic peripheral neuropathy and/or neuropathic inflammation in a patient in need of such treatment.

Claims

1. A pharmaceutical formulation comprising at least two compounds, one effecting opioid analgesia and one effecting cyclooxygenase 1 and 2 activity, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient.

2. The topical pharmaceutical composition according to claim 1 comprising at least one analgesic and wherein the analgesic is selected from the group consisting of an opiate, an opiate derivative, an opioid, enkephalins, endorphins and synthetic opioid peptides.

3. The topical pharmaceutical composition according to claim 2, wherein the opioid is selected from the group consisting of ethylmorphine, hydromorphone, morphine, oxymorphone, codeine, levorphanol, oxycodone, hydrocodone, pentazocine, propoxyphene, fentanyl, sufentanil, lofentanil, morphine-6-glucuronide, loperamide, meperidine, tramadol, naloxone, naltrexone, buprenorphine, methadone, etorphine, [D-Ala², MePhe⁴, Gly⁵-ol]enkephaline (DAMGO), butorphanol, nalorphine, nalbuphine, naloxone benzyolhydrazone, bremazocine, ethylketocyclazocine, U-50488, U-69593, spiradoline, naltrindole, [D-Pen², D-Pen⁵]enkephalin (DPDPE), [D-Ala², Glu⁴,]deltorphin, and [D-Ser², Leu⁵]enkephalin-Thr⁶ (DSLET).

4. The topical pharmaceutical composition according to claim 1, wherein the cyclooxygenase 1 and 2 activity effecting compound is a non-steroidal anti-inflammatory drug (NSAID).

5. The topical pharmaceutical composition according to claim 4, wherein the NSAID is selected from the group consisting of ibuprofen, ketoprofen, flurbiprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, alminoprofen, butibufen, diclofenac, ketorolac, aspirin, acetaminophen, celebrex and rofecoxib.

6. The topical pharmaceutical composition according to claim 1, wherein the analgesic is morphine and the NSAID is ibuprofen.

7. The topical pharmaceutical composition according to claim 1, wherein the analgesic is morphine and the NSAID is diclofenac.

8. The topical pharmaceutical composition according to claim 1, wherein the analgesic is methadone and the NSAID is ibuprofen.

9. The topical pharmaceutical composition according to claim 1, wherein the analgesic is methadone and the NSAID is diclofenac.

10. The topical pharmaceutical composition according to claim 1, wherein the analgesic is hydrocodone and the NSAID is diclofenac.

11. The topical pharmaceutical composition according to claim 1, wherein the analgesic is hydrocodone and the NSAID is ibuprofen.

12. The topical pharmaceutical composition according to claim 1, wherein the opioid analgesic is present in a dose of about 0.001% to about 10%.

13. The topical pharmaceutical composition according to claim 1, wherein the NSAIDs is present in a dose of about 0.01% to about 20%.

14. The topical formulation according to claim 1, wherein said topical formulation is in the form of solution, suspension, gel, emugel, cream, ointment, lotion, spray or transdermal patch.

15. The topical combination of the skin penetration enhancers according to any of the preceding claims 1 to 14, wherein combination of propylene glycol and lauric acid in ratio 10:

1 work synergistically.

16. Use of at least two compounds, one effecting opioid analgesia and one effecting cyclooxygenase 1 and 2 activity, for the production of a topical pharmaceutical combination to prevent or relieve acute incisional pain and chronic peripheral neuropathy in a patient in need of such treatment.

18. Use according to claim 16 or 17, wherein the administration of the pharmaceutical composition is directed to cutaneous, mucosal, vaginal, rectal, ocular, or nasal surfaces.

17. Use of at least two compounds, one effecting opioid analgesia and one effecting cyclooxygenase 1 and 2 activity, for the production of a topical pharmaceutical combination to prevent or relieve neuropathic inflammation in a patient in need of such treatment.